Background: 

The efficacy of chemotherapy in locally advanced, recurrent, and metastatic salivary gland carcinomas (LA-R/M SGCs) is still undefined. We aimed to compare the efficacy of two chemotherapy regimens in LA-R/M SGC.

Materials and Methods: 

This prospective study compared paclitaxel (Taxol) plus carboplatin (TC) versus cyclophosphamide, doxorubicin, plus cisplatin (CAP) regimen in terms of overall response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS).

Results: 

Between October 2011 and April 2019, 48 patients with LA-R/M SGCs were recruited. The ORRs of first-line TC and CAP regimens were 54.2% and 36.3%, respectively (P = 0.57). The ORRs in recurrent and de novo metastatic patients were 50.0% and 37.5% for TC and CAP, respectively (P = 0.26). The median PFS of TC and CAP arms were 10.2 and 11.9 months, respectively (P = 0.91). In the subanalysis, patients with adenoid cystic carcinoma (ACC) had longer PFS in the TC arm (14.5 vs. 8.2 months, P = 0.03), irrespective of the tumor grade (low grade: 16.3 vs. 8.9 months, high grade: 11.7 vs. 4.5 months; P = 0.03). The median OS rates were 45.5 and 19.5 months for TC and CAP groups, respectively (P = 0.71).

Conclusion: 

For patients with LA-R/M SGC, there was no significant difference between first-line TC and CAP in terms of ORR, PFS, and OS.

中文翻译：

---

晚期、复发性或转移性唾液腺癌两种化疗方案的比较

背景： 

化疗对局部晚期、复发性和转移性唾液腺癌 (LA-R/M SGC) 的疗效仍不清楚。我们的目的是比较两种化疗方案对 LA-R/M SGC 的疗效。

材料和方法： 

这项前瞻性研究比较了紫杉醇 (Taxol) 加卡铂 (TC) 与环磷酰胺、阿霉素加顺铂 (CAP) 方案的总体缓解率 (ORR)、临床获益率 (CBR)、无进展生存期 (PFS) 和总生存期（OS）。

结果： 

2011年10月至2019年4月期间，招募了48名患有LA-R/M SGC的患者。一线TC和CAP方案的ORR分别为54.2%和36.3%（P =0.57）。TC 和 CAP 复发和初发转移患者的 ORR分别为 50.0% 和 37.5%（P = 0.26）。TC 组和 CAP 组的中位 PFS 分别为 10.2 个月和 11.9 个月（P = 0.91）。在亚分析中，无论肿瘤分级如何，腺样囊性癌 (ACC) 患者在 TC 组中的 PFS 较长（14.5 个月与 8.2 个月，P = 0.03）（低级别：16.3 个月与 8.9 个月，高级别：11.7 vs. 4.5 个月；P= 0.03）。TC 组和 CAP 组的中位 OS 率分别为 45.5 个月和 19.5 个月（P = 0.71）。

结论： 

对于 LA-R/M SGC 患者，一线 TC 和 CAP 在 ORR、PFS 和 OS 方面没有显着差异。